Supplemental Figure 1.A. Frequency of CCND1 aberrations by tumor type. Included primary cancer diagnosis with N ≥ 20. See Supplemental Table 1 for complete.

Slides:

Advertisements

Similar presentations

Tennessee High School Survey Summary Graphs Percentage of students who: Note: This graph contains weighted results. See the corresponding summary tables.

Advertisements

Case 5 M, 78 ys Violaceous plaque on the penis History of nodal Mantle Cell Lymphoma (courtesy Prof. A. Maiorana)

Supplemental Figure 1 A No. at risk T T T

P449. p450 Figure 15-1 p451 Figure 15-2 p453 Figure 15-2a p453.

Mitogens stimulate G1-Cdk and G1/S-Cdk activities.

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

Figure Figure 18-1 part 1 Figure 18-1 part 2.

1 times table 2 times table 3 times table 4 times table 5 times table

© Cancer Research UK 2008 Registered charity number Incidence – UK February 2008.

 decimals/cc-7th-fracs-to-decimals/v/converting-fractions-to-decimals-example.

Supplemental data 2. Breast cancer primary tumor, metastasis and xenograft Total copy number gain (green), loss (red) and unchanged (black) for primary.

By the end of this lesson you will be able to explain/calculate the following: 1. Mean for data in frequency table 2. Mode for data in frequency table.

Percentage without a calculator 10% 10%, 20 %, 30% …. 90% 25%, 50% or 75% 33 ⅓ % and 66 ⅔ % 5% 15%, 25%, 35% etc Mixture.

Excercises on chapter 2. Exercises on chapter 2 Complete the table,then answer the following questions Text Book : Basic Concepts and Methodology for.

$100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300.

Chapter Sixteen: Production Costs. Types of Production Costs.

Module 4: How do unrealistic expectations confound the results of our analyses Case Studies in Bioinformatics Giovanni Ciriello

Cancer Chapter 4 Supplement. Cancer - important facts Cancer is uncontrolled cell growth It requires several steps to form It is very different depending.

The Burden of Cancer in Connecticut Lou Gonsalves Connecticut Tumor Registry

Supplementary Figure 1A Supplementary Figure 1A. Highlighting mutation calls that arise within two specific regions of the NFE2L2 gene from the TCGA UCEC.

Tables Learning Support

Shimura Supplemental Figure 1

Charles M. Rudin, MD, PhD, Alexander Drilon, MD, J.T. Poirier, PhD

Strategy Description Discovery Validation Application

Figures & Tables from the textbook.

A C Tumour Chromosome 8 Tumour Chromosome 8 B D Tumour Chromosome 17

Mark G. Erlander, Xiao-Jun Ma, Nicole C

Revealing the genomic heterogeneity of melanoma

Volume 150, Issue 3, Pages (September 2018)

CSCI2950-C Lecture 3 September 13, 2007.

Supplemental Figure 1 A B C

The Variance How to calculate it.

Identification of a MEK2 mutation in a melanoma sample resistant to dabrafenib/trametinib. Identification of a MEK2 mutation in a melanoma sample resistant.

4155 primary hepatocellular carcinoma with known diagnosis month/year

Volume 141, Issue 1, Pages e23-e26 (July 2011)

Figure S2 Supplementary data a b CCA1 CCA2 CCA4 CCA3 CCA5 EGFR HER2

Identification of Drivers of Aneuploidy in Breast Tumors

14. Calculate the percentage of selections for each item within each presentation session. Here is the data collected from the previous clip across each.

Cyclin E1 Is Amplified and Overexpressed in Osteosarcoma

Supplemental Figure 1 1 mutation 2 mutations 3 mutations 4 mutations

Neoantigen-specific TCR expansion in stimulated T-cell cultures.

Unit 3 Review (Calculator)

Charles M. Rudin, MD, PhD, Alexander Drilon, MD, J.T. Poirier, PhD

Fig. 6. FGFR1 and CCND1 amplification–mediated resistance to estrogen deprivation is therapeutically actionable. FGFR1 and CCND1 amplification–mediated.

Supplemental Figure 1 – Age Distribution in the CAC Consortium

Assessing the frequency of somatic mutation from single dog hairs—Forensic testing of StockMarks® Canine I Ver3 kit P. Zenke, B. Egyed, Z. Szabolcsi,

Figure 2: | The p53 core domain is shown as a tetramer bound to DNA from two different rotation angles. a | Residues affected by the five most common tumour-associated.

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Figure Overview.

Figure Overview.

Averages: Mean from a Frequency Table

Supplemental Data.

Thymoma and Thymic Carcinoma: Molecular Pathology and Targeted Therapy

3 times tables.

6 times tables.

Calculate 9 x 81 = x 3 3 x 3 x 3 x 3 3 x 3 x 3 x 3 x 3 x 3 x =

Percentage Practice © T Madas.

Canonical gliomagenesis mediators EGFR, P53, and retinoblastoma protein (RB1) are important for cancer signaling. Canonical gliomagenesis mediators EGFR,

Squamous Cell Cancers: A Unified Perspective on Biology and Genetics

MYD88 L265P + CCND3 I290R + QC2-03 QC2-05 QC2-11 QC2-12 QC2-13 QC2-19

Diagonal lines were shown.

KIT mutations in GISTs. A, amino acid sequence of KIT exon 11 mutations in clinical GIST biopsies. –, amino acids that are deleted; italicized amino acids,

Chapter 1 Functions.

Representative photograph of somatic mutations detected by PCR-SSCP.

Distribution of FGFR aberrancies in urothelial cancers.

Location of the ER mutations and frequencies per cohort.

Relative frequencies of FGFR aberrations in non–small cell lung carcinoma. Relative frequencies of FGFR aberrations in non–small cell lung carcinoma. A,

Presentation transcript:

Supplemental Figure 1.A. Frequency of CCND1 aberrations by tumor type. Included primary cancer diagnosis with N ≥ 20. See Supplemental Table 1 for complete list of cancer diagnosis with N < 20. Frequencies of aberration were calculated as a percentage of the number of tumors of that type.

Supplemental Figure 1.B. Frequency of CCND2 aberrations by tumor type. Included primary cancer diagnosis with N ≥ 20. See Supplemental Table 1 for complete list of cancer diagnosis with N < 20. Frequencies of aberration were calculated as a percentage of the number of tumors of that type.

Supplemental Figure 1.C. Frequency of CCND3 aberration by tumor type. Included primary cancer diagnosis with N ≥ 20. See Supplemental Table 1 for complete list of cancer diagnosis with N < 20. Frequencies of aberration were calculated as a percentage of the number of tumors of that type.

Supplemental Figure 1.D. Frequency of CDK4 amplification by tumor type. Included primary cancer diagnosis with N ≥ 20. See Supplemental Table 1 for complete list of cancer diagnosis with N < 20. Frequencies of aberration were calculated as a percentage of the number of tumors of that type.

Supplemental Figure 1.E. Frequency of CDK6 amplification by tumor type. Included primary cancer diagnosis with N ≥ 20. See Supplemental Table 1 for complete list of cancer diagnosis with N < 20. Frequencies of aberration were calculated as a percentage of the number of tumors of that type.

Supplemental Figure 1.F. Frequency of CDKN2A/B aberrations by tumor type. Included primary cancer diagnosis with N ≥ 20. See Supplemental Table 1 for complete list of cancer diagnosis with N < 20. Frequencies of aberration were calculated as a percentage of the number of tumors of that type.

Supplemental Figure 1.G. Frequency of CCNE1 aberrations by tumor type. Included primary cancer diagnosis with N ≥ 20. See Supplemental Table 1 for complete list of cancer diagnosis with N < 20. Frequencies of aberration were calculated as a percentage of the number of tumors of that type.

Supplemental Figure 1.H. Frequency of RB1 aberrations by tumor type. Included primary cancer diagnosis with N ≥ 20. See Supplemental Table 1 for complete list of cancer diagnosis with N < 20. Frequencies of aberration were calculated as a percentage of the number of tumors of that type.

Supplemental Figure 2.A. Comparison of CCND1 aberrations between current report and cBioPortal data ( * * cBioPortal data available for mutation only. Included 10 most common cancer diagnoses associated with CCND1 aberrations from current report and when cBioPortal data were available for corresponding diagnosis. Data from cBioPortal are highlighted in diagonal patterns.

Supplemental Figure 2.B. Comparison of CCND2 aberrations between current report and cBioPortal data ( * * * cBioPortal data available for mutation only. Included 10 most common cancer diagnoses associated with CCND2 aberration from current report and when cBioPortal data were available for corresponding diagnosis. Data from cBioPortal are highlighted in diagonal patterns.

Supplemental Figure 2.C. Comparison of CCND3 aberrations between current report and cBioPortal data ( * * cBioPortal data available for mutation only. Included 10 most common cancer diagnoses associated with CCND3 aberration from current report and when cBioPortal data were available for corresponding diagnosis. Data from cBioPortal are highlighted in diagonal patterns.

Supplemental Figure 2.D. Comparison of CDK4 aberrations between current report and cBioPortal data ( * * cBioPortal data available for mutation only. Included 10 most common cancer diagnoses associated with CDK4 aberration from current report and when cBioPortal data were available for corresponding diagnosis. Data from cBioPortal are highlighted in diagonal patterns.

Supplemental Figure 2.E. Comparison of CDK6 aberrations between current report and cBioPortal data ( * * * cBioPortal data available for mutation only. Included 10 most common cancer diagnoses associated with CDK6 aberration from current report and when cBioPortal data were available for corresponding diagnosis. Data from cBioPortal are highlighted in diagonal patterns.

Supplemental Figure 2.F. Comparison of CDKN2A/B aberrations between current report and cBioPortal data ( * * * cBioPortal data available for mutation only. Included 10 most common cancer diagnoses associated with CDKN2A/B aberration from current report and when cBioPortal data were available for corresponding diagnosis. Data from cBioPortal are highlighted in diagonal patterns.

Supplemental Figure 2.G. Comparison of CCNE1 aberrations between current report and cBioPortal data ( * * * cBioPortal data available for mutation only. Included 10 most common cancer diagnoses associated with CCNE1 aberration from current report and when cBioPortal data were available for corresponding diagnosis. Data from cBioPortal are highlighted in diagonal patterns.

Supplemental Figure 2.H. Comparison of RB1 aberrations between current report and cBioPortal data ( * * * * cBioPortal data available for mutation only. Included 10 most common cancer diagnoses associated with RB1 aberration from current report and when cBioPortal data were available for corresponding diagnosis. Data from cBioPortal are highlighted in diagonal patterns.